300194 福安药业
已收盘 11-22 15:00:00
资讯
新帖
简况
福安药业(300194.SZ)：化学原料药头孢托仑匹酯上市申请获得批准
智通财经 · 11-22 16:04
福安药业(300194.SZ)：化学原料药头孢托仑匹酯上市申请获得批准
福安药业11月21日现1笔大宗交易 成交金额1175.76万元
新浪证券-红岸工作室 · 11-21 17:00
福安药业11月21日现1笔大宗交易 成交金额1175.76万元
11月21日福安药业现1笔溢价13.37%的大宗交易 合计成交1175.76万元
证券之星 · 11-21 16:45
11月21日福安药业现1笔溢价13.37%的大宗交易 合计成交1175.76万元
福安药业最新公告：拟投资4.28亿元建设原料药绿色化、智能化高端生产场地建设项目
证券之星 · 11-20
福安药业最新公告：拟投资4.28亿元建设原料药绿色化、智能化高端生产场地建设项目
福安药业(300194.SZ)子公司拟4.28亿元投建原料药绿色化、智能化高端生产场地建设项目
智通财经网 · 11-20
福安药业(300194.SZ)子公司拟4.28亿元投建原料药绿色化、智能化高端生产场地建设项目
福安药业最新公告：子公司博圣制药收到化学原料药上市申请批准通知书
证券之星 · 11-12
福安药业最新公告：子公司博圣制药收到化学原料药上市申请批准通知书
福安药业(300194.SZ)子公司收到苯唑西林钠化学原料药上市申请批准通知书
智通财经 · 11-12
福安药业(300194.SZ)子公司收到苯唑西林钠化学原料药上市申请批准通知书
福安药业最新公告：尼麦角林原料药获得韩国药品注册证书
证券之星 · 11-08
福安药业最新公告：尼麦角林原料药获得韩国药品注册证书
福安药业11月7日现1笔大宗交易 成交金额609.9万元
新浪证券-红岸工作室 · 11-07
福安药业11月7日现1笔大宗交易 成交金额609.9万元
11月7日福安药业现609.9万元大宗交易
证券之星 · 11-07
11月7日福安药业现609.9万元大宗交易
福安药业：TING HE、SHI YUAN ZHU等多人因涉嫌违反证券法律法规等违规行为被证监会责令改正
证券之星 · 11-06
福安药业：TING HE、SHI YUAN ZHU等多人因涉嫌违反证券法律法规等违规行为被证监会责令改正
福安药业：TING HE、WEI GUO CHEN等多人因未依法履行其他职责被深圳证券交易所公开谴责
证券之星 · 11-06
福安药业：TING HE、WEI GUO CHEN等多人因未依法履行其他职责被深圳证券交易所公开谴责
福安药业最新公告：收到对相关承诺方行政监管措施决定书
证券之星 · 11-05
福安药业最新公告：收到对相关承诺方行政监管措施决定书
福安药业：收到行政监管措施决定书
美港电讯 · 11-05
福安药业：收到行政监管措施决定书
福安药业(300194.SZ)：瑞巴派特片获药品注册证书
智通财经 · 11-05
福安药业(300194.SZ)：瑞巴派特片获药品注册证书
福安药业最新公告：前三季度净利润同比增长19.76%
证券之星 · 10-24
福安药业最新公告：前三季度净利润同比增长19.76%
福安药业(300194.SZ)发布前三季度业绩，净利润3.02亿元，同比增长19.76%
智通财经 · 10-24
福安药业(300194.SZ)发布前三季度业绩，净利润3.02亿元，同比增长19.76%
福安药业最新公告：子公司获化学原料药上市批准
证券之星 · 10-23
福安药业最新公告：子公司获化学原料药上市批准
福安药业：子公司吡贝地尔化学原料药上市申请获批
美港电讯 · 10-23
福安药业：子公司吡贝地尔化学原料药上市申请获批
福安药业(300194.SZ)收到吡贝地尔化学原料药上市申请批准通知书
智通财经网 · 10-23
福安药业(300194.SZ)收到吡贝地尔化学原料药上市申请批准通知书
公司概况
公司名称：
福安药业(集团)股份有限公司
所属行业：
医药制造业
上市日期：
2011-03-22
主营业务：
福安药业(集团)股份有限公司主要从事化学药品的研发、生产、销售。主要产品有抗生素类（包括原料药、制剂不同规格）、抗肿瘤类、特色专科药类等药物。
发行价格：
41.88
{"stockData":{"symbol":"300194","market":"SZ","secType":"STK","nameCN":"福安药业","latestPrice":4.78,"timestamp":1732259022000,"preClose":5.01,"halted":0,"volume":34848000,"delay":0,"floatShares":968000000,"shares":1190000000,"eps":0.2368,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.23,"latestTime":"11-22 15:00:00","open":5.01,"high":5.09,"low":4.78,"amount":172000000,"amplitude":0.0619,"askPrice":4.79,"askSize":2301,"bidPrice":4.78,"bidSize":4054,"shortable":0,"etf":0,"ttmEps":0.2368,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":5.01,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":5.51,"lowLimit":4.51,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1189712382,"pbRate":1.35,"roa":"--","roe":"7.06%","epsLYR":0.19,"committee":0.046202,"marketValue":5687000000,"floatMarketCap":4626000000,"peRate":20.185811,"changeRate":-0.0459,"turnoverRate":0.036,"status":1},"requestUrl":"/m/hq/s/300194/wiki","defaultTab":"wiki","newsList":[{"id":"2485123882","title":"福安药业(300194.SZ)：化学原料药头孢托仑匹酯上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2485123882","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485123882?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:04","pubTimestamp":1732262647,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)公告，公司全资子公司福安药业集团重庆博圣制药有限公司(简称“博圣制药”)于近日收到国家药品监督管理局签发的化学原料药上市申请批准通知书(头孢托仑匹酯)。头孢托仑匹酯临床主要用于敏感菌所致的呼吸道、泌尿道、皮肤软组织感染等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0132","BK0060","300194","BK0028"],"gpt_icon":0},{"id":"2485745426","title":"福安药业11月21日现1笔大宗交易 成交金额1175.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485745426","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485745426?lang=zh_cn&edition=full","pubTime":"2024-11-21 17:00","pubTimestamp":1732179600,"startTime":"0","endTime":"0","summary":" 11月21日，福安药业收涨0.80%，收盘价为5.01元，发生1笔大宗交易，合计成交量207万股，成交金额1175.76万元。 进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为1785.66万元。该股近5个交易日累计上涨0.40%，主力资金合计净流出4211.94万元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-11-21/doc-incwvitk4609540.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-21/doc-incwvitk4609540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0132","BK0239","BK0060","BK0028","300194"],"gpt_icon":0},{"id":"2485245179","title":"11月21日福安药业现1笔溢价13.37%的大宗交易 合计成交1175.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485245179","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485245179?lang=zh_cn&edition=full","pubTime":"2024-11-21 16:45","pubTimestamp":1732178702,"startTime":"0","endTime":"0","summary":"证券之星消息，11月21日福安药业发生大宗交易，交易数据如下：大宗交易成交价格5.68元，相对当日收盘价溢价13.37%，成交207万股，成交金额1175.76万元，买方营业部为华泰证券股份有限公司张家港金港镇长江中路证券营业部，卖方营业部为华泰证券股份有限公司张家港金港镇长江中路证券营业部。截至2024年11月21日收盘，福安药业报收于5.01元，上涨0.8%，换手率3.12%，成交量30.17万手，成交额1.5亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112100025934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300194","BK0060","BK0028","BK0132","BK0239"],"gpt_icon":0},{"id":"2484219561","title":"福安药业最新公告：拟投资4.28亿元建设原料药绿色化、智能化高端生产场地建设项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2484219561","media":"证券之星","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484219561?lang=zh_cn&edition=full","pubTime":"2024-11-20 18:40","pubTimestamp":1732099215,"startTime":"0","endTime":"0","summary":"福安药业公告，公司全资子公司博圣制药拟投资建设“原料药绿色化、智能化高端生产场地建设项目”，项目预计总投资为4.28亿元，以自有资金或银行贷款投资建设。项目建设期预计为两年。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000032159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","300194","BK0028","BK0060"],"gpt_icon":0},{"id":"2484981193","title":"福安药业(300194.SZ)子公司拟4.28亿元投建原料药绿色化、智能化高端生产场地建设项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2484981193","media":"智通财经网","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484981193?lang=zh_cn&edition=full","pubTime":"2024-11-20 18:33","pubTimestamp":1732098802,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业 发布公告，公司审议通过了《关于子公司拟投资建设项目的议案》，同意公司全资子公司福安药业集团重庆博圣制药有限公司投资建设“原料药绿色化、智能化高端生产场地建设项目”。该项目的建设主要为满足博圣制药未来发展需要，提高生产能力，适应市场需求，随着近年公司原料药产品注册陆续获批，对博圣制药产能要求逐步加大，着眼于未来发展，拟建设上述项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0132","BK0239","BK0060","BK0028","300194"],"gpt_icon":0},{"id":"2482962727","title":"福安药业最新公告：子公司博圣制药收到化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2482962727","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482962727?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:45","pubTimestamp":1731401158,"startTime":"0","endTime":"0","summary":"福安药业公告，公司全资子公司博圣制药近日收到国家药品监督管理局签发的化学原料药上市申请批准通知书，原料药名称为苯唑西林钠，登记号为Y20230000208，包装规格为5kg/听。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200026726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0028","BK0132","BK1191","300194","BK1574","01477"],"gpt_icon":0},{"id":"2482724278","title":"福安药业(300194.SZ)子公司收到苯唑西林钠化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2482724278","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482724278?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:30","pubTimestamp":1731400241,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)发布公告，公司全资子公司福安药业集团重庆博圣制药有限公司(简称“博圣制药”)于近日收到国家药品监督管理局签发的苯唑西林钠化学原料药上市申请批准通知书。苯唑西林钠主要用于耐青霉素葡萄球菌所致的各种感染，包括败血症、呼吸道感染、脑膜炎、软组织感染等。也可用于化脓性链球菌或肺炎球菌与耐青霉素葡萄球菌所致的混合感染。上述原料药产品获得上市批准将可以在国内上市制剂中使用，将进一步丰富子公司产品线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300194","BK0028","BK0060","BK0132","BK0239"],"gpt_icon":0},{"id":"2481121353","title":"福安药业最新公告：尼麦角林原料药获得韩国药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481121353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481121353?lang=zh_cn&edition=full","pubTime":"2024-11-08 18:20","pubTimestamp":1731061258,"startTime":"0","endTime":"0","summary":"福安药业公告，全资子公司博圣制药于近日收到韩国食品药品监督管理局原料药品注册证书。尼麦角林适用于急性或慢性脑血管障碍或脑代谢功能不良。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800032419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300194","BK0028","BK0132","BK0239","BK0060"],"gpt_icon":0},{"id":"2481922273","title":"福安药业11月7日现1笔大宗交易 成交金额609.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481922273","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481922273?lang=zh_cn&edition=full","pubTime":"2024-11-07 17:00","pubTimestamp":1730970000,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 第1笔成交价格为5.35元，成交114.00万股，成交金额609.90万元，溢价率为3.68%，买方营业部为华泰证券股份有限公司张家港金港镇长江中路证券营业部，卖方营业部为华泰证券股份有限公司张家港金港镇长江中路证券营业部。 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为609.9万元。该股近5个交易日累计上涨5.95%，主力资金合计净流出660.18万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-11-07/doc-incvfuhw9012397.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-07/doc-incvfuhw9012397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0028","BK0060","BK0132","300194"],"gpt_icon":0},{"id":"2481924033","title":"11月7日福安药业现609.9万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2481924033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481924033?lang=zh_cn&edition=full","pubTime":"2024-11-07 16:55","pubTimestamp":1730969742,"startTime":"0","endTime":"0","summary":"证券之星消息，11月7日福安药业发生大宗交易，交易数据如下：大宗交易成交价格5.35元，相对当日收盘价溢价3.68%，成交114万股，成交金额609.9万元，买方营业部为华泰证券股份有限公司张家港金港镇长江中路证券营业部，卖方营业部为华泰证券股份有限公司张家港金港镇长江中路证券营业部。截至2024年11月7日收盘，福安药业报收于5.16元，上涨4.45%，换手率7.76%，成交量75.11万手，成交额3.8亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110700027902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","300194","BK0028","BK0239","BK0060"],"gpt_icon":0},{"id":"2481384696","title":"福安药业：TING HE、SHI YUAN ZHU等多人因涉嫌违反证券法律法规等违规行为被证监会责令改正","url":"https://stock-news.laohu8.com/highlight/detail?id=2481384696","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481384696?lang=zh_cn&edition=full","pubTime":"2024-11-06 01:00","pubTimestamp":1730826039,"startTime":"0","endTime":"0","summary":"证券之星消息，11月5日福安药业公开信息显示，TING HE、SHI YUAN ZHU、WEI GUO CHEN因涉嫌违反证券法律法规,未依法履行其他职责被中国证券监督管理委员会重庆监管局责令改正。处罚决定如下：责令你三人限期改正,在收到本决定之日起180日内,SHI YUAN ZHU应履行回购义务,TING HE和WEI GUO CHEN应承担连带担保责任以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600000489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","BK0239","300194","BK0132","161027"],"gpt_icon":0},{"id":"2481263846","title":"福安药业：TING HE、WEI GUO CHEN等多人因未依法履行其他职责被深圳证券交易所公开谴责","url":"https://stock-news.laohu8.com/highlight/detail?id=2481263846","media":"证券之星","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481263846?lang=zh_cn&edition=full","pubTime":"2024-11-06 01:00","pubTimestamp":1730826034,"startTime":"0","endTime":"0","summary":"证券之星消息，11月5日福安药业公开信息显示，TING HE、WEI GUO CHEN、SHI YUAN ZHU因未依法履行其他职责被深圳证券交易所公开谴责。详细违规行为如下：2019年9月5日,福安药业(集团)股份有限公司与SHIYUANZHU、TINGHE、RedRealtyLLC签署《股权购买和增资协议》,福安药业以7,300万美元取得RedRealtyLLC51%的股权。截至本纪律处分决定书出具之日,SHIYUANZHU、TINGHE和WEIGUOCHEN未按照公开披露的信息履行业绩补偿承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600000487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0132","BK0028","300194"],"gpt_icon":1},{"id":"2481736535","title":"福安药业最新公告：收到对相关承诺方行政监管措施决定书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481736535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481736535?lang=zh_cn&edition=full","pubTime":"2024-11-05 18:30","pubTimestamp":1730802649,"startTime":"0","endTime":"0","summary":"福安药业公告，公司于2024年11月5日收到中国证券监督管理委员会重庆监管局《关于对SHI YUAN ZHU、TING HE和WEI GUO CHEN采取责令改正行政监管措施的决定》。监管局责令SHI YUAN ZHU在收到决定书之日起180日内履行回购义务，TING HE和WEI GUO CHEN承担连带担保责任。本次监管措施不会影响公司正常经营管理活动。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500031278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0028","BK0132","300194"],"gpt_icon":0},{"id":"2481578922","title":"福安药业：收到行政监管措施决定书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481578922","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481578922?lang=zh_cn&edition=full","pubTime":"2024-11-05 18:19","pubTimestamp":1730801985,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0028","BK0060","BK4081","BK0239","SHI","HE","300194","WEI","BK0132","BK4166","BK4090"],"gpt_icon":0},{"id":"2481522833","title":"福安药业(300194.SZ)：瑞巴派特片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481522833","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481522833?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:24","pubTimestamp":1730798657,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)公告，公司全资子公司福安药业集团宁波天衡制药有限公司(简称“天衡药业”)于近日收到国家药品监督管理局签发的药品注册证书，药品名称为：瑞巴派特片。瑞巴派特片主要适用于胃溃疡，急性胃炎、慢性胃炎的急性加重期胃粘膜病变(糜烂、出血、充血、水肿)的改善。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300194","BK0028","BK0132","BK0239","BK0060"],"gpt_icon":0},{"id":"2477653034","title":"福安药业最新公告：前三季度净利润同比增长19.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477653034","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477653034?lang=zh_cn&edition=full","pubTime":"2024-10-24 23:01","pubTimestamp":1729782083,"startTime":"0","endTime":"0","summary":"福安药业发布2024年第三季度报告，前三季度实现营业收入19.95亿元，同比增长0.62%；归属于上市公司股东的净利润3.02亿元，同比增长19.76%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400038750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300194"],"gpt_icon":0},{"id":"2477687145","title":"福安药业(300194.SZ)发布前三季度业绩，净利润3.02亿元，同比增长19.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477687145","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477687145?lang=zh_cn&edition=full","pubTime":"2024-10-24 20:16","pubTimestamp":1729772184,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)发布2024年第三季度报告，公司前三季度营业收入19.95亿元，同比增长0.62%;归属于上市公司股东的净利润3.02亿元，同比增长19.76%;归属于上市公司股东的扣除非经常性损益的净利润2.83亿元，同比增长25.43%;基本每股收益0.25元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1199200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300194"],"gpt_icon":0},{"id":"2477149372","title":"福安药业最新公告：子公司获化学原料药上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2477149372","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477149372?lang=zh_cn&edition=full","pubTime":"2024-10-23 16:16","pubTimestamp":1729671382,"startTime":"0","endTime":"0","summary":"福安药业公告，全资子公司福安药业集团重庆博圣制药有限公司近日收到国家药品监督管理局签发的化学原料药上市申请批准通知书。原料药名称为吡贝地尔。吡贝地尔可作为单药治疗，或与左旋多巴联合用药用于帕金森病的治疗。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300026044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300194","BK0132","BK0239","BK0028","BK0060"],"gpt_icon":0},{"id":"2477371890","title":"福安药业：子公司吡贝地尔化学原料药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2477371890","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477371890?lang=zh_cn&edition=full","pubTime":"2024-10-23 15:55","pubTimestamp":1729670116,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300194","BK1574","BK1191","BK0060","01477","BK0132","BK0028","BK0239"],"gpt_icon":0},{"id":"2477337948","title":"福安药业(300194.SZ)收到吡贝地尔化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2477337948","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477337948?lang=zh_cn&edition=full","pubTime":"2024-10-23 15:50","pubTimestamp":1729669817,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福安药业(300194.SZ)发布公告，公司全资子公司福安药业集团重庆博圣制药有限公司(简称“博圣制药”)于近日收到国家药品监督管理局签发的化学原料药上市申请批准通知书。原料药名称为吡贝地尔，吡贝地尔可作为单药治疗，或与左旋多巴联合用药用于帕金森病的治疗。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0060","300194","BK0028","BK0132","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-03-22","address":"重庆市长寿区化南一路1号","stockEarnings":[{"period":"1week","weight":-0.0185},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.2256},{"period":"6month","weight":0.1805},{"period":"1year","weight":0.0106},{"period":"ytd","weight":0.1052}],"companyName":"福安药业(集团)股份有限公司","boardCode":"AI0027","perCapita":"23966股","boardName":"医药制造业","registeredCapital":"118971万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":" 福安药业(集团)股份有限公司主要从事化学药品的研发、生产、销售。主要产品有抗生素类（包括原料药、制剂不同规格）、抗肿瘤类、特色专科药类等药物。","serverTime":1732428876188,"listedPrice":41.88,"stockholders":"40384人(较上一季度增加0.39%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福安药业(300194)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福安药业(300194)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福安药业,300194,福安药业股票,福安药业股票老虎,福安药业股票老虎国际,福安药业行情,福安药业股票行情,福安药业股价,福安药业股市,福安药业股票价格,福安药业股票交易,福安药业股票购买,福安药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福安药业(300194)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福安药业(300194)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}